Research On Antigen-Specific Immune Response After Targeting Antigen To DC-SIGN

while evidences demonstrating that significant improvement have been made after vaccine-based treatment in many serious infections, the challenges to vaccine biology still exist, especially when appearance of various novel infectious diseases and increase of mortality from cancers. Exploiting new strategy to improve immunogenity of vaccine for therapy purpose is needed.Dendritic cells(DCs) are so far more potent profesional antigen presenting cells(pAPCs), compared with others pAPCs, which could uptake and present exogenous antigen efficiently via receptors mediated endocytosis, macropinocytosis and phagocytosis. As a natural immune adjuvant, DCs could enhance expressions of some costimulatory factors such as CD80, CD86 during encountering some"dangerous signals", which would be as a second signal for activating effector T cells including na?ve T cells in cooperation with antigen peptide-MHC complex, a first signal from DCs. DCs, as a pAPC and natural immune adjuvant, could initiate appropriate immune responses after presenting processed antigen to T cells, which provide many hopes for exploiting DCs to improve vaccine's efficacy.Targeting vaccine to DCs is an important and convenient strategy for exploiting DCs to enhance vaccine immunogenicity. Till now, many antigen receptors on DCs were identified. Selection of an appropriate receptor should be important for vaccine targeted to DCs successfully.DC-SIGN, a C-type lectin-like receptors, is mostly expressed by immature DCs. DC-SIGN acts as an antigen receptor. So far, studies of immune function of DC-SIGN have demonstrated which could efficiently capture a variety of pathogens such as HIV and CMV virions at the low concentration in the mucosa tissues. Then DCs can presented these antigens in MHC-II and MHC-I restricted fashions. DC-SIGN has been characterized by efficient capture of pathogens and restricted expression on DCs, which makes it be a...